Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Poseida Therapeutics ( (PSTX) ) has provided an update.
Poseida Therapeutics has completed a merger where it has become a wholly owned subsidiary of a Parent company. As a result of the merger, the company has delisted its shares from Nasdaq and plans to terminate its registration and reporting obligations with the SEC. The merger agreement also led to changes in the company’s board and leadership structure.
More about Poseida Therapeutics
YTD Price Performance: 1.06%
Average Trading Volume: 1,694,304
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $931.8M
Learn more about PSTX stock on TipRanks’ Stock Analysis page.